See the published version of this preprint at BMC Gastroenterology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Shirin Shahbazi
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Gastric cancer (GC) is a world health problem and it is the third leading cause of cancer deaths worldwide. The current practice for prognosis assessment in GC is based on radiological and pathological criteria and they may not result in an accurate prognosis. The aim of this study is to evaluate expression and copy number variation of the ADAR gene in advanced GC and clarify its correlation with survival and histopathological characteristics.
Methods
Forty two patients with stage III and IV GC were included in this study. ADAR gene expression and copy number variation were measured by real-time PCR and Quantitative multiplex fluorescent-PCR, respectively. Survival analysis performed based on the Kaplan–Meier method and Mantel–Cox test.
Results
ADAR mRNA was significantly overexpressed in the tumor tissues when compared to the adjacent normal tissues (p <0.01). Also, ADAR expression level in stage IV was higher than stage III. 40% of patients showed amplification in ADAR gene and there was a positive correlation between ADAR copy number and expression. Increased ADAR expression was clearly correlated with poorer survival outcomes and Mantel–Cox test showed statistically significant differences between low and high expression groups (p <0.0001). ADAR overexpression and amplification were significantly associated with metastasis, size and stage of tumor.
Conclusions
Together, our data indicate that amplification leads to over expression of ADAR and it could be used as a prognostic biomarker for disease progression, especially for the metastatic process in GC.
Keywords
Gastric cancer, ADAR gene, Overexpression, Amplification, Prognosis
Keywords
Gastric cancer, ADAR gene, Overexpression, Amplification, Prognosis
Figure 1
Figure 2
Figure 3
Figure 4
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Gastroenterology.
No community comments so far
Editorial decision: Accept
On 06 May, 2020
Reviewer #2 agreed
On 04 May, 2020
Review #2 received
Received 04 May, 2020
Review #1 received
Received 30 Apr, 2020
Reviewer #1 agreed
On 23 Apr, 2020
Reviewers invited
Invitations sent on 22 Apr, 2020
Editor assigned
On 21 Apr, 2020
Submission checks complete
On 20 Apr, 2020
Editor invited
On 20 Apr, 2020
Version 1
Posted 27 Jan, 2020
No comments provided
Editorial decision: Minor revision
On 05 Mar, 2020
Review #2 received
Received 04 Mar, 2020
Reviewer #2 agreed
On 04 Mar, 2020
Review #1 received
Received 22 Feb, 2020
Reviewer #1 agreed
On 08 Feb, 2020
Reviewers invited
Invitations sent on 05 Feb, 2020
First submitted
On 22 Jan, 2020
Editor assigned
On 22 Jan, 2020
Submission checks complete
On 21 Jan, 2020
Editor invited
On 21 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Gastroenterology & Hepatology
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Gastroenterology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Shirin Shahbazi
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Gastroenterology.
No community comments so far
Editorial decision: Accept
On 06 May, 2020
Reviewer #2 agreed
On 04 May, 2020
Review #2 received
Received 04 May, 2020
Review #1 received
Received 30 Apr, 2020
Reviewer #1 agreed
On 23 Apr, 2020
Reviewers invited
Invitations sent on 22 Apr, 2020
Editor assigned
On 21 Apr, 2020
Submission checks complete
On 20 Apr, 2020
Editor invited
On 20 Apr, 2020
Version 1
Posted 27 Jan, 2020
No comments provided
Editorial decision: Minor revision
On 05 Mar, 2020
Review #2 received
Received 04 Mar, 2020
Reviewer #2 agreed
On 04 Mar, 2020
Review #1 received
Received 22 Feb, 2020
Reviewer #1 agreed
On 08 Feb, 2020
Reviewers invited
Invitations sent on 05 Feb, 2020
First submitted
On 22 Jan, 2020
Editor assigned
On 22 Jan, 2020
Submission checks complete
On 21 Jan, 2020
Editor invited
On 21 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Gastroenterology & Hepatology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Gastroenterology.
Background
Gastric cancer (GC) is a world health problem and it is the third leading cause of cancer deaths worldwide. The current practice for prognosis assessment in GC is based on radiological and pathological criteria and they may not result in an accurate prognosis. The aim of this study is to evaluate expression and copy number variation of the ADAR gene in advanced GC and clarify its correlation with survival and histopathological characteristics.
Methods
Forty two patients with stage III and IV GC were included in this study. ADAR gene expression and copy number variation were measured by real-time PCR and Quantitative multiplex fluorescent-PCR, respectively. Survival analysis performed based on the Kaplan–Meier method and Mantel–Cox test.
Results
ADAR mRNA was significantly overexpressed in the tumor tissues when compared to the adjacent normal tissues (p <0.01). Also, ADAR expression level in stage IV was higher than stage III. 40% of patients showed amplification in ADAR gene and there was a positive correlation between ADAR copy number and expression. Increased ADAR expression was clearly correlated with poorer survival outcomes and Mantel–Cox test showed statistically significant differences between low and high expression groups (p <0.0001). ADAR overexpression and amplification were significantly associated with metastasis, size and stage of tumor.
Conclusions
Together, our data indicate that amplification leads to over expression of ADAR and it could be used as a prognostic biomarker for disease progression, especially for the metastatic process in GC.
Keywords
Gastric cancer, ADAR gene, Overexpression, Amplification, Prognosis
Figure 1
Figure 2
Figure 3
Figure 4
Loading...